WITHDRAWN: Immunogenicity and safety of HCV E1E2 peptide vaccine in chronically HCV-infected patients who did not respond to interferon based therapy

Mostafa K El-Awady; Mohamed El Gendy; Imam Waked; Ashraf A Tabll; Yasmin El Abd; Noha Bader El Din; Reem El Shenawy; Aleef Allam; Tawfeek H Abdelhafez; Reham M Dawood

doi:10.1016/j.vaccine.2013.07.074

WITHDRAWN: Immunogenicity and safety of HCV E1E2 peptide vaccine in chronically HCV-infected patients who did not respond to interferon based therapy

Vaccine. 2013 Aug 17:S0264-410X(13)01065-7. doi: 10.1016/j.vaccine.2013.07.074. Online ahead of print.

Affiliations

¹ Microbial Biotechnology Department, National Research Center, Dokki, 12622 Giza, Egypt. Electronic address: mkawady49@yahoo.com.
² National Liver Institute, Shebeen El Kom, Menofyia University, Egypt.
³ Microbial Biotechnology Department, National Research Center, Dokki, 12622 Giza, Egypt.

PMID: 23962537
DOI: 10.1016/j.vaccine.2013.07.074

Abstract

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.